Literature DB >> 16380919

NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.

Alessandro De Luca1, Irene Bottillo, Anna Sarkozy, Claudio Carta, Cinzia Neri, Emanuele Bellacchio, Annalisa Schirinzi, Emanuela Conti, Giuseppe Zampino, Agatino Battaglia, Silvia Majore, Maria M Rinaldi, Massimo Carella, Bruno Marino, Antonio Pizzuti, Maria Cristina Digilio, Marco Tartaglia, Bruno Dallapiccola.   

Abstract

Neurofibromatosis type 1 (NF1) demonstrates phenotypic overlap with Noonan syndrome (NS) in some patients, which results in the so-called neurofibromatosis-Noonan syndrome (NFNS). From a genetic point of view, NFNS is a poorly understood condition, and controversy remains as to whether it represents a variable manifestation of either NF1 or NS or is a distinct clinical entity. To answer this question, we screened a cohort with clinically well-characterized NFNS for mutations in the entire coding sequence of the NF1 and PTPN11 genes. Heterozygous NF1 defects were identified in 16 of the 17 unrelated subjects included in the study, which provides evidence that mutations in NF1 represent the major molecular event underlying this condition. Lesions included nonsense mutations, out-of-frame deletions, missense changes, small inframe deletions, and one large multiexon deletion. Remarkably, a high prevalence of inframe defects affecting exons 24 and 25, which encode a portion of the GAP-related domain of the protein, was observed. On the other hand, no defect in PTPN11 was observed, and no lesion affecting exons 11-27 of the NF1 gene was identified in 100 PTPN11 mutation-negative subjects with NS, which provides further evidence that NFNS and NS are genetically distinct disorders. These results support the view that NFNS represents a variant of NF1 and is caused by mutations of the NF1 gene, some of which have been demonstrated to cause classic NF1 in other individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380919      PMCID: PMC1285166          DOI: 10.1086/498454

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  56 in total

1.  SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

Authors:  N Guex; M C Peitsch
Journal:  Electrophoresis       Date:  1997-12       Impact factor: 3.535

Review 2.  Neurofibromatosis-Noonan syndrome.

Authors:  J C Carey
Journal:  Am J Med Genet       Date:  1998-01-23

3.  Novel recurrent nonsense mutation causing neurofibromatosis type 1 (NF1) in a family segregating both NF1 and Noonan syndrome.

Authors:  M Bahuau; C Houdayer; B Assouline; C Blanchet-Bardon; M Le Merrer; S Lyonnet; S Giraud; D Récan; H Lakhdar; M Vidaud; D Vidaud
Journal:  Am J Med Genet       Date:  1998-01-23

4.  Exclusion of allelism of Noonan syndrome and neurofibromatosis-type 1 in a large family with Noonan syndrome-neurofibromatosis association.

Authors:  M Bahuau; W Flintoff; B Assouline; S Lyonnet; M Le Merrer; M Prieur; M Guilloud-Bataille; N Feingold; A Munnich; M Vidaud; D Vidaud
Journal:  Am J Med Genet       Date:  1996-12-18

Review 5.  SHP-2 and myeloid malignancies.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Kevin M Shannon; Mignon L Loh
Journal:  Curr Opin Hematol       Date:  2004-01       Impact factor: 3.284

6.  Structural analysis of the GAP-related domain from neurofibromin and its implications.

Authors:  K Scheffzek; M R Ahmadian; L Wiesmüller; W Kabsch; P Stege; F Schmitz; A Wittinghofer
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

7.  Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients.

Authors:  V M Park; E K Pivnick
Journal:  J Med Genet       Date:  1998-10       Impact factor: 6.318

8.  Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

Authors:  L E Side; P D Emanuel; B Taylor; J Franklin; P Thompson; R P Castleberry; K M Shannon
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

9.  Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature.

Authors:  Marjolijn Jongmans; Erik A Sistermans; Alwin Rikken; Willy M Nillesen; Rienk Tamminga; Michael Patton; Esther M Maier; Marco Tartaglia; Kees Noordam; Ineke van der Burgt
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

10.  Phenotypic and genotypic characterisation of Noonan-like/multiple giant cell lesion syndrome.

Authors:  J S Lee; M Tartaglia; B D Gelb; K Fridrich; S Sachs; C A Stratakis; M Muenke; P G Robey; M T Collins; A Slavotinek
Journal:  J Med Genet       Date:  2005-02       Impact factor: 6.318

View more
  46 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  Extensive Retropharyngeal and Spinal Plexiform Neurofibromas in a Neonate with Type 1-Neurofibromatosis.

Authors:  Meghmala Sadhukhan; Brendon Conry; Bim Bhaduri
Journal:  Indian J Pediatr       Date:  2017-04-25       Impact factor: 1.967

4.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

5.  LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria.

Authors:  Atilano Carcavilla; Isabel Pinto; Rafael Muñoz-Pacheco; Raquel Barrio; Maria Martin-Frías; Begoña Ezquieta
Journal:  Eur J Pediatr       Date:  2011-03-02       Impact factor: 3.183

6.  Familial spinal neurofibromatosis due to a multiexonic NF1 gene deletion.

Authors:  Antonio Pizzuti; Irene Bottillo; Francesca Inzana; Valentina Lanari; Francesca Buttarelli; Isabella Torrente; Anna Teresa Giallonardo; Alessandro De Luca; Bruno Dallapiccola
Journal:  Neurogenetics       Date:  2011-03-02       Impact factor: 2.660

Review 7.  On the value of homogeneous constructs for construct validation, theory testing, and the description of psychopathology.

Authors:  Gregory T Smith; Denis M McCarthy; Tamika C B Zapolski
Journal:  Psychol Assess       Date:  2009-09

8.  A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Kadri Karaer; Martin Zenker; Arzu Ekici; Kürşat Bora Carman
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

9.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

10.  Neurofibromatosis type 1 (NF1) associated with tumor of the corpus callosum.

Authors:  Ignacio Pascual-Castroviejo; Samuel-Ignacio Pascual-Pascual
Journal:  Childs Nerv Syst       Date:  2012-09-22       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.